医疗ETF 09:00事件流｜2026-08-26至27（20条）

[ { "event_id": "CNINFO-CN-20260826-CHENGDUXIANLEAD-H1", "title": "成都先导上半年营收增 52.41%", "event_time_utc": "2026-08-26T07:51:00Z", "event_time_quality": "exact", "published_at_utc": "2026-08-26T07:51:00Z", "event_type": "sales_data", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 1 }, "confidence": 96, "horizon": "days", "raw_facts": "成都先导 2026 年上半年营业收入 345,979,084.89 元，同比增长 52.41%；归属于上市公司股东的净利润 80,675,253.74 元，同比增长 61.21%；扣除非经常性损益后的归母净利润同比增长 42.80%。", "transmission_chain": "上半年营业收入、归母净利润和扣非归母净利润分别同比增长 52.41%、61.21%和 42.80%→成都先导收入与两种利润口径均同比增长→该公司创新药研发服务预期边际改善，MEDICAL 方向取+1。", "invalidation_conditions": "后续公告更正收入或利润数字；订单、交付或客户结构变化导致下半年增长显著放缓。", "source_urls": [ "http://static.cninfo.com.cn/finalpage/2026-08-27/1225508330.PDF" ], "source_tier": "A" }, { "event_id": "CNINFO-CN-20260826-NAWEI-H1", "title": "纳微科技上半年净利增 116.11%", "event_time_utc": "2026-08-26T08:51:00Z", "event_time_quality": "exact", "published_at_utc": "2026-08-26T08:51:00Z", "event_type": "sales_data", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 1 }, "confidence": 96, "horizon": "days", "raw_facts": "纳微科技 2026 年上半年营业收入 56,783.37 万元，同比增长 37.28%；归属于上市公司股东的净利润 13,680.78 万元，同比增长 116.11%；扣除非经常性损益后的归母净利润同比增长 130.47%。", "transmission_chain": "上半年营业收入、归母净利润和扣非归母净利润分别同比增长 37.28%、116.11%和 130.47%→纳微科技收入与两种利润口径均同比增长→该公司生物制药供应链业务预期边际改善，MEDICAL 方向取+1。", "invalidation_conditions": "后续公告对收入、归母净利润或扣非归母净利润数字进行更正；下半年营业收入或扣非归母净利润同比转负。", "source_urls": [ "http://static.cninfo.com.cn/finalpage/2026-08-27/1225509811.PDF" ], "source_tier": "A" }, { "event_id": "HKEX-HK-20260826-JUNSHI-H1", "title": "君实生物上半年营收增 45%", "event_time_utc": "2026-08-26T09:02:00Z", "event_time_quality": "exact", "published_at_utc": "2026-08-26T09:02:00Z", "event_type": "sales_data", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 2 }, "confidence": 96, "horizon": "days", "raw_facts": "君实生物 2026 年上半年总收入约人民币 1,696 百万元，同比增长 45%；核心产品 TUOYI（特瑞普利单抗 JS001）国内销售收入约人民币 1,299 百万元，同比增长 36%；对外授权相关收入增加约人民币 152 百万元，同比增长 149%；归属于公司股东的利润为人民币 26 百万元，较 2025 年同期增加约人民币 439 百万元。", "transmission_chain": "特瑞普利单抗国内销售同比增长 36%，对外授权相关收入增加约人民币 152 百万元，归属于公司股东的利润为人民币 26 百万元→核心产品销售、授权收入和公司利润均有当期数据支持→君实生物创新药商业化预期边际改善，MEDICAL 方向取+2。", "invalidation_conditions": "正式全年业绩更正本条所列收入、产品收入或利润数字；核心产品收入同比增速转负或全年指引下修。", "source_urls": [ "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0826/2026082600488.pdf" ], "source_tier": "A" }, { "event_id": "CNINFO-CN-20260826-DABO-H1", "title": "大博医疗上半年净利增 44.65%", "event_time_utc": "2026-08-26T09:09:00Z", "event_time_quality": "exact", "published_at_utc": "2026-08-26T09:09:00Z", "event_type": "sales_data", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 1 }, "confidence": 96, "horizon": "days", "raw_facts": "大博医疗 2026 年上半年营业收入 1,339,884,360.68 元，同比增长 10.69%；归属于上市公司股东的净利润 353,331,905.24 元，同比增长 44.65%；扣除非经常性损益后的归母净利润同比增长 25.10%。", "transmission_chain": "上半年营业收入、归母净利润和扣非归母净利润分别同比增长 10.69%、44.65%和 25.10%→大博医疗收入与两种利润口径均同比增长→该公司医疗器械业务预期边际改善，MEDICAL 方向取+1。", "invalidation_conditions": "后续公告更正本条所列收入、归母净利润或扣非归母净利润数字；下半年收入或扣非归母净利润同比转负。", "source_urls": [ "http://static.cninfo.com.cn/finalpage/2026-08-27/1225509570.PDF" ], "source_tier": "A" }, { "event_id": "HKEX-HK-20260826-HANSOH-H1", "title": "翰森制药创新药收入占比升至 85.4%", "event_time_utc": "2026-08-26T09:21:00Z", "event_time_quality": "exact", "published_at_utc": "2026-08-26T09:21:00Z", "event_type": "sales_data", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 1 }, "confidence": 96, "horizon": "days", "raw_facts": "翰森制药 2026 年上半年收入约人民币 8,304 百万元，同比增长 11.7%；创新药收入约人民币 7,092 百万元，同比增长 15.4%，占总收入比例约 85.4%；研发支出约人民币 1,739 百万元，同比增长 20.7%，占收入约 20.9%。", "transmission_chain": "总收入同比增长 11.7%，创新药收入同比增长 15.4%且占总收入约 85.4%→创新药收入增速高于总收入，产品结构变化有当期财务数据支持→该公司创新药商业化预期边际改善，MEDICAL 方向取+1。", "invalidation_conditions": "后续公告更正本条所列收入、创新药收入或研发支出数字；创新药收入同比增速转负。", "source_urls": [ "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0826/2026082600590.pdf", "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0826/2026082600616.pdf" ], "source_tier": "A" }, { "event_id": "CNINFO-CN-20260826-JIDAN-H1", "title": "基蛋生物上半年净利增 69.37%", "event_time_utc": "2026-08-26T09:24:00Z", "event_time_quality": "exact", "published_at_utc": "2026-08-26T09:24:00Z", "event_type": "sales_data", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 1 }, "confidence": 96, "horizon": "days", "raw_facts": "基蛋生物 2026 年上半年营业收入 555,336,020.64 元，同比增长 8.32%；归属于上市公司股东的净利润 184,291,348.06 元，同比增长 69.37%；扣除非经常性损益后的归母净利润同比增长 26.63%。", "transmission_chain": "上半年营业收入同比增长 8.32%，归母净利润同比增长 69.37%，扣非归母净利润同比增长 26.63%→两种利润口径均同比增长，扣非口径提供更保守的经营改善证据→该公司体外诊断业务预期边际改善，MEDICAL 方向取+1。", "invalidation_conditions": "后续公告更正本条所列收入、归母净利润或扣非归母净利润数字；下半年营业收入或扣非归母净利润同比转负。", "source_urls": [ "http://static.cninfo.com.cn/finalpage/2026-08-27/1225511037.PDF" ], "source_tier": "A" }, { "event_id": "HKEX-HK-20260826-BEONE-H1", "title": "百济神州上半年收入增 32.3%", "event_time_utc": "2026-08-26T10:00:00Z", "event_time_quality": "exact", "published_at_utc": "2026-08-26T10:00:00Z", "event_type": "sales_data", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 2 }, "confidence": 98, "horizon": "days", "raw_facts": "百济神州（BeOne Medicines）2026 年上半年总收入 3,218.5 百万美元，同比增长 32.3%；产品收入净额 3,167.1 百万美元，同比增长 31.4%；净利润 464.4 百万美元，2025 年同期为 95.6 百万美元；BRUKINSA 收入 2,342.483 百万美元，2025 年同期为 1,741.504 百万美元；TEVIMBRA 收入 434.756 百万美元。", "transmission_chain": "收入和产品收入分别同比增长 32.3%和 31.4%，净利润达到 464.4 百万美元→百济神州商业化销售和公司盈利能力得到半年报数据验证→该公司盈利预期边际改善，MEDICAL 方向取+2。", "invalidation_conditions": "正式全年业绩更正本条所列收入、利润或产品销售数字；BRUKINSA 或 TEVIMBRA 收入同比增速转负。", "source_urls": [ "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0826/2026082600783.pdf", "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0826/2026082600784_c.pdf" ], "source_tier": "A" }, { "event_id": "HKEX-HK-20260826-SYS6010-P3", "title": "石药 SYS6010 三期达到预设主要终点", "event_time_utc": "2026-08-26T10:01:00Z", "event_time_quality": "exact", "published_at_utc": "2026-08-26T10:01:00Z", "event_type": "clinical_data", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 2 }, "confidence": 94, "horizon": "weeks", "raw_facts": "石药集团公告：EGFR 靶向抗体偶联药物 SYS6010 的随机、开放标签、多中心 SYNSTAR-01 III 期研究，对照铂类化疗，入组 EGFR TKI 治疗失败的 EGFR 突变型局部晚期或转移性非小细胞肺癌患者；独立数据监察委员会审查确认研究达到预设主要终点，研究组无进展生存期显著优于铂类化疗，具有统计学显著性和临床意义，总生存期（OS）呈获益趋势，安全性良好。", "transmission_chain": "EGFR ADC 三期主要终点阳性→SYS6010 后续完整数据披露及注册申报预期增强→该产品后续开发预期边际改善，MEDICAL 方向取+2。", "invalidation_conditions": "完整数据、学术会议或期刊披露与公告结论不一致；后续监管沟通不支持注册申报或项目撤回。", "source_urls": [ "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0826/2026082600791.pdf" ], "source_tier": "A" }, { "event_id": "HKEX-HK-20260826-SYS6090-FASTTRACK", "title": "石药 SYS6090 获 FDA 快速通道资格", "event_time_utc": "2026-08-26T10:09:00Z", "event_time_quality": "exact", "published_at_utc": "2026-08-26T10:09:00Z", "event_type": "regulation", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 1 }, "confidence": 95, "horizon": "weeks", "raw_facts": "石药集团公告：SYS6090（JMT108）为 PD-1/IL-15 双特异性融合蛋白，获得美国 FDA Fast Track designation，适应症为标准全身治疗进展后的 MSS/pMMR 转移性结直肠癌。", "transmission_chain": "FDA 快速通道资格认定→公司获得后续开发与审评沟通通道，但不等同疗效结论或上市批准→SYS6090 开发进度预期边际改善，MEDICAL 方向取+1。", "invalidation_conditions": "FDA 后续否认或撤销资格；I 期临床安全性、药效或开发进度不支持继续推进。", "source_urls": [ "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0826/2026082600825.pdf" ], "source_tier": "A" }, { "event_id": "CNINFO-CN-20260826-HAOYUAN-H1", "title": "皓元医药上半年营收增 25.71%", "event_time_utc": "2026-08-26T10:36:00Z", "event_time_quality": "exact", "published_at_utc": "2026-08-26T10:36:00Z", "event_type": "sales_data", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 1 }, "confidence": 96, "horizon": "days", "raw_facts": "皓元医药 2026 年上半年营业收入 1,647,974,323.92 元，同比增长 25.71%；归属于上市公司股东的净利润 171,200,366.68 元，同比增长 12.81%；扣除非经常性损益后的归母净利润同比增长 10.21%。", "transmission_chain": "上半年营业收入、归母净利润和扣非归母净利润分别同比增长 25.71%、12.81%和 10.21%→皓元医药收入与两种利润口径均同比增长→该公司创新药研发服务预期边际改善，MEDICAL 方向取+1。", "invalidation_conditions": "后续公告更正本条所列收入、归母净利润或扣非归母净利润数字；下半年收入或扣非归母净利润同比转负。", "source_urls": [ "http://static.cninfo.com.cn/finalpage/2026-08-27/1225513093.PDF" ], "source_tier": "A" }, { "event_id": "HKEX-HK-20260826-BOAN-BA2201-IND", "title": "博安生物 BA2201 IND 获 CDE 受理", "event_time_utc": "2026-08-26T11:00:00Z", "event_time_quality": "exact", "published_at_utc": "2026-08-26T11:00:00Z", "event_type": "regulation", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 1 }, "confidence": 95, "horizon": "weeks", "raw_facts": "博安生物 BA2201 为靶向 TL1A 与 IL-23 的长效双特异性抗体，拟用于炎症性肠病，包括克罗恩病和溃疡性结肠炎；其 IND 申请已获国家药监局药品审评中心（CDE）受理。公告披露的临床前事实包括阻断 TL1A-DR3 结合、抑制 IL-23 信号，食蟹猴半衰期支持人体每 3 个月给药一次。", "transmission_chain": "BA2201 的 IND 申请获 CDE 受理→该申请进入 CDE 审评流程，但不等同获准开展临床→BA2201 国内开发进度预期边际改善，MEDICAL 方向取+1。", "invalidation_conditions": "CDE 退回或拒绝该 IND 申请；公司撤回申请；后续公告证明本条所述受理信息有误。", "source_urls": [ "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0826/2026082601121.pdf" ], "source_tier": "A" }, { "event_id": "CNINFO-CN-20260826-XINMAI-H1", "title": "心脉医疗上半年营收增 11.13%", "event_time_utc": "2026-08-26T11:04:00Z", "event_time_quality": "exact", "published_at_utc": "2026-08-26T11:04:00Z", "event_type": "sales_data", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 1 }, "confidence": 97, "horizon": "days", "raw_facts": "心脉医疗 2026 年上半年营业收入 793,949,008.92 元，同比增长 11.13%；归属于上市公司股东的净利润 322,362,360.92 元，同比增长 2.45%；扣除非经常性损益后的归母净利润同比增长 10.45%。", "transmission_chain": "上半年营业收入同比增长 11.13%，扣非归母净利润同比增长 10.45%，但归母净利润仅同比增长 2.45%→公司收入和经常性利润保持增长，归母利润弹性有限→该公司经营预期边际改善但强度受限，MEDICAL 方向取+1。", "invalidation_conditions": "后续公告更正本条所列收入或利润数字；下半年收入或扣非归母净利润同比转负。", "source_urls": [ "http://static.cninfo.com.cn/finalpage/2026-08-27/1225513909.PDF" ], "source_tier": "A" }, { "event_id": "CNINFO-CN-20260826-SHENGXIANG-H1", "title": "圣湘生物上半年净利降 39.76%", "event_time_utc": "2026-08-26T11:20:00Z", "event_time_quality": "exact", "published_at_utc": "2026-08-26T11:20:00Z", "event_type": "sales_data", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": -1 }, "confidence": 96, "horizon": "days", "raw_facts": "圣湘生物 2026 年上半年营业收入 834,318,517.89 元，同比下降 3.95%；归属于上市公司股东的净利润 98,017,339.57 元，同比下降 39.76%；扣除非经常性损益后的归母净利润同比下降 60.48%。", "transmission_chain": "上半年营业收入同比下降 3.95%，归母净利润和扣非归母净利润分别同比下降 39.76%和 60.48%→圣湘生物收入与两种利润口径均承压→该公司诊断业务预期偏负面，MEDICAL 方向取-1。", "invalidation_conditions": "后续公告更正本条所列收入或利润数字；下半年收入或扣非归母净利润同比转正。", "source_urls": [ "http://static.cninfo.com.cn/finalpage/2026-08-27/1225514237.PDF" ], "source_tier": "A" }, { "event_id": "CNINFO-CN-20260826-NANWEI-H1", "title": "南微医学上半年增收不增利", "event_time_utc": "2026-08-26T11:30:00Z", "event_time_quality": "exact", "published_at_utc": "2026-08-26T11:30:00Z", "event_type": "sales_data", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": -1 }, "confidence": 97, "horizon": "days", "raw_facts": "南微医学 2026 年上半年营业收入 1,727,947,419.23 元，同比增长 10.39%；归属于上市公司股东的净利润 303,425,747.12 元，同比下降 16.50%；扣除非经常性损益后的归母净利润同比下降 18.33%。", "transmission_chain": "上半年营业收入同比增长 10.39%，归母净利润和扣非归母净利润分别同比下降 16.50%和 18.33%→南微医学收入增长未转化为利润增长→该公司器械业务盈利预期短线承压，MEDICAL 方向取-1。", "invalidation_conditions": "后续公告更正本条所列收入或利润数字；下半年利润率或利润增速显著修复。", "source_urls": [ "http://static.cninfo.com.cn/finalpage/2026-08-27/1225514413.PDF" ], "source_tier": "A" }, { "event_id": "SEC-US-20260826-CELCUITY-GEDATOLISIB-SNDA", "title": "Celcuity 提交 gedatolisib 补充新药申请", "event_time_utc": null, "event_time_quality": "day_only", "published_at_utc": "2026-08-26T12:35:14Z", "event_type": "regulation", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 2 }, "confidence": 91, "horizon": "weeks", "raw_facts": "Celcuity 向 FDA 提交 REVTORPYK（gedatolisib）补充新药申请（sNDA），拟扩展至 PIK3CA 突变的 HR+/HER2-局部晚期或转移性乳腺癌；VIKTORIA-1 III 期 PIK3CA 突变队列纳入 350 例，三联方案相对 alpelisib+fulvestrant 的疾病进展或死亡风险 HR 为 0.50（95% CI 0.37–0.68，p<0.0001），中位无进展生存期 11.1 个月对 5.6 个月；双联方案 HR 为 0.51（95% CI 0.33–0.79，描述性 p=0.0013），中位无进展生存期 11.3 个月对 5.6 个月；三联和双联客观缓解率分别为 49%和 36%，缓解持续时间中位数分别为 15.7 个月和 24.2 个月。", "transmission_chain": "PIK3CA 突变乳腺癌 sNDA 提交并附带 III 期数据→为 REVTORPYK 适应症扩展审评提供申报与临床依据，但尚不等同 FDA 批准→该产品适应症扩展预期边际改善，MEDICAL 方向取+2。", "invalidation_conditions": "FDA 拒绝受理或发出完整回复信；后续数据未维持无进展生存获益。", "source_urls": [ "[https://www.[sec.gov/Archives/edgar/data/1603454/000119312526365975/celc-ex99_1.htm](https://www.sec.gov/Archives/edgar/data/1603454/000119312526365975/celc-ex99_1.htm)](https://sec.gov/Archives/edgar/data/1603454/000119312526365975/celc-ex99_1.htm](https://www.sec.gov/Archives/edgar/data/1603454/000119312526365975/celc-ex99_1.htm))" ], "source_tier": "A" }, { "event_id": "CNINFO-CN-20260826-YAHUILONG-H1", "title": "亚辉龙上半年净利增 166.97%", "event_time_utc": "2026-08-26T12:50:00Z", "event_time_quality": "exact", "published_at_utc": "2026-08-26T12:50:00Z", "event_type": "sales_data", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 1 }, "confidence": 96, "horizon": "days", "raw_facts": "亚辉龙 2026 年上半年营业收入 887,959,565.80 元，同比增长 9.84%；归属于上市公司股东的净利润 70,130,828.34 元，同比增长 166.97%；扣除非经常性损益后的归母净利润同比增长 46.81%。", "transmission_chain": "上半年营业收入同比增长 9.84%，归母净利润同比增长 166.97%，扣非归母净利润同比增长 46.81%→归母利润增速高于扣非利润，后者为更保守的经营改善口径→该公司盈利预期边际改善，MEDICAL 方向取+1。", "invalidation_conditions": "后续公告更正本条所列收入或利润数字；下半年收入或扣非归母净利润同比转负。", "source_urls": [ "http://static.cninfo.com.cn/finalpage/2026-08-27/1225515260.PDF", "http://static.cninfo.com.cn/finalpage/2026-08-27/1225515271.PDF" ], "source_tier": "A" }, { "event_id": "MHRA-GB-20260826-COBALT-CHROME-HIP-DSI", "title": "MHRA 警示钴铬模块化髋关节风险", "event_time_utc": null, "event_time_quality": "day_only", "published_at_utc": "2026-08-26T13:01:32Z", "event_type": "regulation", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": -1 }, "confidence": 97, "horizon": "days", "raw_facts": "英国药品和保健品管理局（MHRA）发布器械安全信息，指出部分钴铬模块化颈部髋关节置换系统存在金属磨损和腐蚀风险及翻修手术风险；涉及 Aesculap Metha、Lima H-Max-M、Smith & Nephew SMF、Stryker ABG II、Symbios HARMONY/SPS 等系统。安全信息表列示 Metha 病例 59 例、翻修 7 例，H-Max-M 病例 139 例、翻修 13 例，SMF 病例 12 例、翻修 0 例，ABG II 病例 63 例、翻修 17 例，HARMONY 病例 49 例、翻修 10 例，SPS 病例 597 例、翻修 38 例，并列示不良局部组织反应（ALTR）12 例；相关器械已不再在英国供应。", "transmission_chain": "英国监管机构提示特定髋关节系统磨损、腐蚀和翻修风险→所列受影响系统及其生产商面临供应与合规不确定性→相关系统的安全监管信号偏负面，MEDICAL 方向取-1。", "invalidation_conditions": "MHRA 后续修订病例或风险范围；制造商完成整改并恢复供应；后续证据否定所列风险关联。", "source_urls": [ "https://www.gov.uk/drug-device-alerts/cobalt-chrome-modular-neck-hip-replacements-risk-of-metal-wear-effects-and-revision-surgery-dsi-slash-2026-slash-010", "https://www.gov.uk/government/news/increased-risk-of-wear-and-corrosion-identified-with-certain-cobalt-chrome-modular-neck-hip-replacements" ], "source_tier": "A" }, { "event_id": "HKEX-HK-20260826-MICOT-MT200605-P2", "title": "麦科奥特 MT200605 二期临床完成", "event_time_utc": "2026-08-26T14:38:00Z", "event_time_quality": "exact", "published_at_utc": "2026-08-26T14:38:00Z", "event_type": "clinical_data", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 2 }, "confidence": 92, "horizon": "weeks", "raw_facts": "麦科奥特 MT200605 为可穿透血脑屏障的小分子 TrkB 激动剂，用于急性缺血性卒中；多中心、随机、双盲、安慰剂对照 II 期试验共入组 360 例受试者，按 1:1:1:1 分为 10mg BID、20mg BID、40mg BID 和安慰剂组，连续静脉输注 14 天。高剂量组改良 Rankin 量表 mRS≤1 比例显著高于安慰剂组，低、中、高剂量呈剂量-反应关系；美国国立卫生研究院卒中量表（NIHSS）改善自第 7 天开始分离，第 14 天更明显；高剂量组急性肾损伤（AKI）发生率较安慰剂组降低超过 80%。", "transmission_chain": "卒中 II 期试验完成并披露高剂量组疗效、安全性信号→MT200605 后续 III 期设计和监管沟通预期增强→该产品后续开发预期边际改善，MEDICAL 方向取+2。", "invalidation_conditions": "完整数据与公告摘要不一致；III 期未达到终点；监管机构质疑 AKI 指标或后续安全性信号恶化。", "source_urls": [ "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0826/2026082602041.pdf" ], "source_tier": "A" }, { "event_id": "FDA-US-20260826-DARAXONRASIB-APPROVAL", "title": "FDA 批准 daraxonrasib 治疗转移性胰腺癌", "event_time_utc": null, "event_time_quality": "day_only", "published_at_utc": "2026-08-26T16:59:36Z", "event_type": "drug_approval", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 3 }, "confidence": 99, "horizon": "weeks", "raw_facts": "美国 FDA 批准 Revolution Medicines 的 RASONQUE（daraxonrasib），用于既往至少接受一线系统治疗或不适合多药系统治疗的转移性胰腺导管腺癌成人患者。RASolute 302 为随机、开放、多中心 III 期研究，共 500 例，daraxonrasib 300mg 每日一次对照研究者选择的标准化疗；全人群中位总生存期 13.2 个月对 6.7 个月，HR 0.40（95% CI 0.30–0.53，p<0.0001）；中位无进展生存期 7.2 个月对 3.6 个月，HR 0.49（95% CI 0.38–0.64，p<0.0001）；客观缓解率 30%对 11%，p<0.0001。", "transmission_chain": "FDA 批准并有 III 期总生存期、无进展生存期和客观缓解率数据支持→daraxonrasib 获得上市监管验证→该药商业化预期边际改善，MEDICAL 方向取+3。", "invalidation_conditions": "FDA 后续更新撤销或限制该批准；上市后披露足以改变获批适应症风险收益判断的重大安全性信号。", "source_urls": [ "[https://www.[fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer](https://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer)](https://fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer](https://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer))", "[https://www.[fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma)](https://fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma))", "[https://ir.[revmed.com/news-releases/news-release-details/us-fda-approves-revolution-medicines-rasonquetm-daraxonrasib](https://ir.revmed.com/news-releases/news-release-details/us-fda-approves-revolution-medicines-rasonquetm-daraxonrasib)](https://revmed.com/news-releases/news-release-details/us-fda-approves-revolution-medicines-rasonquetm-daraxonrasib](https://ir.revmed.com/news-releases/news-release-details/us-fda-approves-revolution-medicines-rasonquetm-daraxonrasib))", "[https://www.[globenewswire.com/news-release/2026/08/26/3351615/0/en/u-s-fda-approves-revolution-medicines-rasonque-daraxonrasib-the-first-broad-ras-targeted-medicine-in-metastatic-pancreatic-cancer.html](https://www.globenewswire.com/news-release/2026/08/26/3351615/0/en/u-s-fda-approves-revolution-medicines-rasonque-daraxonrasib-the-first-broad-ras-targeted-medicine-in-metastatic-pancreatic-cancer.html)](https://globenewswire.com/news-release/2026/08/26/3351615/0/en/u-s-fda-approves-revolution-medicines-rasonque-daraxonrasib-the-first-broad-ras-targeted-medicine-in-metastatic-pancreatic-cancer.html](https://www.globenewswire.com/news-release/2026/08/26/3351615/0/en/u-s-fda-approves-revolution-medicines-rasonque-daraxonrasib-the-first-broad-ras-targeted-medicine-in-metastatic-pancreatic-cancer.html))" ], "source_tier": "A" }, { "event_id": "CMS-US-20260827-NEOGENOMICS-RADAR-ST-COVERAGE", "title": "CMS MolDX 扩大 RaDaR ST 医保覆盖", "event_time_utc": null, "event_time_quality": "day_only", "published_at_utc": "2026-08-27T00:17:00Z", "event_type": "medical_insurance", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 1 }, "confidence": 94, "horizon": "weeks", "raw_facts": "NeoGenomics 公告称，其 RaDaR ST 检测获得 CMS MolDX Medicare 扩展覆盖，用于晚期实体瘤免疫检查点抑制剂治疗反应监测；公司材料列出的相关覆盖场景为：HPV 阴性头颈鳞癌、部分 HR+/HER2-乳腺癌，以及免疫治疗反应监测。", "transmission_chain": "CMS MolDX 扩大 RaDaR ST 的 Medicare 覆盖范围→NeoGenomics 相关检测的支付可及性获得扩展，为该检测使用量增加提供条件→该产品检测需求预期边际改善，MEDICAL 方向取+1。", "invalidation_conditions": "CMS 撤销或限制 MolDX 覆盖；公司后续披露该检测不再适用于本条所列覆盖场景。", "source_urls": [ "[https://ir.[neogenomics.com/news-events/press-releases/detail/337/neogenomics-receives-medicare-coverage-for-radar-st-for-immunotherapy-treatment-response-monitoring](https://ir.neogenomics.com/news-events/press-releases/detail/337/neogenomics-receives-medicare-coverage-for-radar-st-for-immunotherapy-treatment-response-monitoring)](https://neogenomics.com/news-events/press-releases/detail/337/neogenomics-receives-medicare-coverage-for-radar-st-for-immunotherapy-treatment-response-monitoring](https://ir.neogenomics.com/news-events/press-releases/detail/337/neogenomics-receives-medicare-coverage-for-radar-st-for-immunotherapy-treatment-response-monitoring))" ], "source_tier": "A" } ]